Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** SPEC is a 35 year-old, privately-owned company located near the New Orleans airport. SPEC is dedicated to designing and manufacturing high quality and high safety radioactive sources, shielded devices and handling equipment, most recently including radiotherapeutic medical devices. This broad experience has been principally in the field of industrial radiography and has an impeccable record of producing high quality, safe equipment used in very challenging conditions experienced by industrial radiographers. Most recently, SPEC has expanded its portfolio to include sources for temporary high dose rate (HDR) brachytherapy.

**Target Market(s):** SPEC is targeting the United States market initially with plans to commercialization the Lung Brachytherapy Source® in global markets through strategic partnerships.

Key Value Drivers

**Technology:** The technology is intended for non-small cell lung cancer patients with early-stage (T1-T2) disease with poor pulmonary health or other medical issues, which are contraindications for lobectomy. Patients would undergo limited surgical resection to preserve lung function while achieving adequate resection margins, followed by brachytherapy.

**Competitive Advantage:** The Lung Brachytherapy Source will reduce the radiation dose to the surgeon’s hands. The problem with current techniques is the difficulty in precisely delivering the brachytherapy seeds intraoperatively to achieve the proper dose distribution and minimizing the radiation dose to the clinicians performing the procedure.

**Plan & Strategy:** The strategy is to commercialize the Lung Brachytherapy Source® in global markets through strategic partnerships.

*Technology funded by the National Cancer Institute under NIH SBIR # 2R44CA125999-03 and being commercialized under the NIH-CAP*

Management

**Leadership:**
Richard D. Dicharry, President
Kevin J Schehr, Vice President
John J. Munro III, Vice President of Business Development

**Scientific Advisory Board:**
David Wazer, M.D.
Thomas DiPetrillo, M.D.

Research was funded by
NIH SBIR#
2R44CA125999-03

Product Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Research</th>
<th>Pre-clinical</th>
<th>Phase 1 Clinical Study</th>
<th>Phase 2 Clinical Study</th>
<th>Phase 3 Clinical Study</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung Brachytherapy Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Applicator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment Planning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Therapeutic Applications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>